Abstract：
Despite many migraine-specific treatments that became available over the past 5 years, many patients still suffer from debilitating migraine. Emerging and future directions of migraine research and treatment should consider different aspects including revising the headache diagnostic criteria to reflect disease burden and prognosis, developing biomarkers, including genetic, serum, imaging, and deep phenotyping biomarkers to facilitate personalized medicine for headache treatment. Additionally, research should also emphasize identifying novel treatment targets for drug development. In this chapter, we provide an overview of current studies and controversies in the diagnosis of migraine and available research on potential migraine biomarkers. We also discuss potential treatment targets for migraine, including CGRP, PACAP, orexin, non-μ opioid receptors, nitric oxide, BKCa channel, KATP channel, amylin, TRP channels, prolactin, PAR-2, and other potential targets.
摘要：
尽管在过去5年中有许多针对偏头痛的治疗方法，许多患者仍然患有虚弱的偏头痛。偏头痛研究和治疗的新兴和未来方向应考虑不同方面，包括修改头痛诊断标准以反映疾病负担和预后。开发生物标志物，包括遗传,血清,成像,和深层表型生物标志物，以促进头痛治疗的个性化药物。此外,研究还应强调为药物开发确定新的治疗靶点。在这一章中,我们概述了目前在偏头痛诊断方面的研究和争议,以及有关潜在偏头痛生物标志物的现有研究.我们还讨论了偏头痛的潜在治疗目标，包括CGRP,PACAP,orexin,非μ阿片受体，一氧化氮,BKCa通道,KATP通道,胰淀素,TRP通道,催乳素,PAR-2和其他潜在目标。
